This company seems to have been delisted
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
Reason: Rebranded as Zevra Therapeutics
Last recorded trade on: May 3, 2023
Source: https://www.mmm-online.com/home/channel/kempharm-rebrands-to-zevra-therapeutics-doubling-down-on-rare-disease-focus/
KemPharm
KMPH
C$7.95
Share price
-0.34%
Change (1 day)
7.11%
Change (1 year)
Categories
KemPharm (KMPH) - Total liabilities
Total liabilities on the balance sheet as of December 2022 : C$40.68 Million
According to KemPharm's latest financial reports the company's total liabilities are C$40.68 Million. A company’s total liabilities is the sum of all current and non-current debts and obligations.
KemPharm - Total liabilities on balance sheet (from 2014 to 2022)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2022-12-31 | C$40.33 M | 443.47% |
| 2021-12-31 | C$7.42 M | -92.5% |
| 2020-12-31 | C$98.97 M | -10.81% |
| 2019-12-31 | C$0.11 B | -12.7% |
| 2018-12-31 | C$0.12 B | -8.07% |
| 2017-12-31 | C$0.13 B | -0.67% |
| 2016-12-31 | C$0.13 B | 52.4% |
| 2015-12-31 | C$91.33 M | 107.04% |
| 2014-12-31 | C$44.11 M | 55.24% |
| 2013-12-31 | C$28.41 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Jazz Pharmaceuticals JAZZ | C$10.07 B | 24,662.10% | 🇮🇪 Ireland |
 Agile Therapeutics
AGRX | C$50.47 M | 24.07% | 🇺🇸 USA |
 Theravance Biopharma
TBPH | C$0.24 B | 497.53% | Cayman Islands |
 ANI Pharmaceuticals ANIP | C$1.16 B | 2,756.33% | 🇺🇸 USA |